Overall, we utilized multi-omics datasets from the GEO, TCGA, HCCDB, TISCH, and HPA databases to comprehensively explore the impact of G6PC1 on HCC prognosis, metabolic reprogramming, tumor immune microenvironment, drug sensitivity, and immunotherapy potential. This evidence concerns the gene G6PC1 and neoplasm.